At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx). for CNS Germ Cell Tumor. Completed, enrolled 10 participants across 5 sites.
Detailed Summary
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCNS Germ Cell Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedJan 2011
Primary CompletionOct 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJan 5, 2011
Enrollment StartAug 1, 2010
Primary CompletionOct 23, 2019
Study CompletionDec 9, 2019
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 15.5 years ago
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).drug
Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.